Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8011 to 8025 of 8904 results

  1. DyeVert for reducing contrast media in coronary and peripheral angiography (MIB196)

    This advice has been updated and replaced by NICE healthtech guidance 594.

    Withdrawn advice

  2. Leukomed Sorbact for preventing surgical site infection (MIB197)

    This advice has been updated and replaced by NICE healthtech guidance 567.

    Withdrawn advice

  3. The ZedScan as an adjunct to colposcopy in women with suspected cervical intra‑epithelial neoplasia (MIB20)

    This advice has been updated and replaced by NICE diagnostics guidance 32.

    Withdrawn advice

  4. LiverMultiScan for liver disease (MIB181)

    This advice has been updated and replaced by NICE healthtech guidance 655.

    Withdrawn advice

  5. SEM Scanner for pressure ulcer prevention (MIB182)

    This advice has been updated and replaced by NICE medical technologies guidance 51.

    Withdrawn advice

  6. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection.

    Withdrawn advice

  7. Danis stent for acute oesophageal variceal bleeds (MIB185)

    This advice has been updated and replaced by NICE healthtech guidance 574.

    Withdrawn advice

  8. Endo-SPONGE for colorectal anastomotic leakage (MIB188)

    This advice has been updated and replaced by NICE healthtech guidance 605.

    Withdrawn advice

  9. The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

    This advice has been updated and replaced by NICE healthtech guidance 566.

    Withdrawn advice

  10. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE healthtech guidance 620.

    Withdrawn advice

  11. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  12. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    In development Reference number: GID-TA11491 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    In development Reference number: GID-TA11406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development